logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2011 or most recent year available

Part (iv) New hallucinogen inpatient clients by country and age at first use

Country<1515-1920-2425-2930-3435-3940-4445+Age knownAge not knownTotal
Belgium00000000000
Bulgaria00000000000
Czech Republic01000000101
Denmark00000000000
Germany1930000013013
Estonia:::::::::::
Ireland101100000202
Greece00000000000
Spain:::::::::::
France00000000000
Italy:::::::::::
Cyprus00000000000
Latvia:::::::::::
Lithuania:::::::::::
Luxembourg:::::::::::
Hungary00010000101
Malta:::::::::::
Netherlands00000000033
Austria00010000101
Poland2:1:::::::::
Portugal:::::::::::
Romania02010000358
Slovenia:::::::::::
Slovakia00000000000
Finland00000000000
Sweden101000000101
United Kingdom305110000707
Croatia:::::::::6:
Turkey00000000000
Norway:::::::::::
Total120540000291437
 

Notes:

: Indicates no data are available.

(1) Data are from 2010.

(2) Data are from 2009. Data presented in the table come from TDI pilot project. Caution should be made when interpreting the data.

(3) Data are from 1st of April 2010 to 31st March 2011.

The number of treatment clients in each country is listed in [Table TDI-7]

See also Table TDI-11 part(v), part(vi)

‘General notes for interpreting data'’ on the Explanatory notes and help page.

Source:

Reitox national reports 2012- Table TDI Inpatient Treatment Centres

Page last updated: Friday, 26 April 2013